Sagimet Biosciences Inc.

NASDAQ:SGMT

Biotechnology

Healthcare
$10.11 +1.38%

+$0.09 today

Market cap
$711.15M
Beta
3.44
P/E (TTM)
-5.0
EPS (TTM)
-$1.34
52W Low $4.50High $11.41

Volume 0.93M

Average 1.49M

SGMT Sales of Investments

Cash received from selling or redeeming investments.

Sagimet Biosciences Inc.NASDAQ: SGMT

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments dips below year-ago levels

Q1 FY2026 sales of investments of $16.97M fell 10.6% year over year, behind the +75.3% change in trailing-twelve-month sales of investments. Sequentially, it fell 46.0% from the prior quarter. Over 3 fiscal years it compounded at +127.7% a year.

Context

  • Sales of investments increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -10.6% toward the trailing-twelve-month pace of +75.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.97M-46.0% QoQ
Last fiscal yearDec 2025
$111.42M+140.1% YoY
LTMMar 2026
$109.4M+75.3% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.6%——
1 year+140.1%——
3-year CAGR+127.7%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
111.42M USD
Year-over-year change
+140.1%

Sales of Investments vs competitors

How SGMT compares with its peers on the latest reported figures

  • SGMT's LTM Mar 2026 sales of investments of $109.4M is the 6th largest of the 11 companies compared; the peer median is $89.59M.
  • Its year-over-year change of +75.3% is the highest of 8, against a peer median of -23.0%.
  • Over three fiscal years its annual growth of +127.7% compares with a peer median of +50.4%.
SGMT Competitors Peer median
Sales of Investments for SGMT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$366.77M -26.9%+72.4%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$212.37M -43.4%+50.4%3701.1%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$212M -16.7%+13.5%751.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$194.74M -49.2%+73.7%533.6%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$147.6M +8.4%-0.1%207.6%
SGMTSagimet Biosciences Inc.LTM Mar 2026$109.4M +75.3%+127.7%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$31.58M -23.0%——
IMRXImmuneering CorporationLTM Mar 2026$9M -14.3%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 ——0.0%
HUMAHumacyte, Inc.LTM Mar 2026$0 ——0.0%
ZURAZura Bio LimitedLTM Mar 2026$0 ———
Peer median (excluding SGMT) $89.59M-23.0%+50.4%370.6%

Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Depreciation & Amortization0130K000
Deferred Income Tax00000
Stock-Based Compensation1.9M1.88M4.99M5.29M6.45M
Change in Working Capital(55K)4.21M(978K)(1.05M)(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables00120K(907K)929K
Other Working Capital(55K)4.21M(1.1M)(141K)(1.98M)
Other Non-Cash Items883K(215K)98K(1.11M)(8K)
Operating Cash Flow(21.71M)(24.49M)(23.77M)(42.44M)(45.65M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments0(41.45M)(19.62M)(108.09M)(106.86M)
Sales of Investments09.44M32.2M46.4M111.42M
Other Investing Activities00000
Investing Cash Flow0(32.01M)12.58M(61.68M)4.56M
Debt Repayment00000
Common Stock Issued012K89.68M105.75M275K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.07M)(85K)(3.51M)(931K)0
Financing Cash Flow9.74M(73K)86.17M104.82M275K
Effect of Forex Changes00000
Net Change in Cash(11.97M)(56.57M)74.98M701K(40.82M)
Free Cash Flow(21.71M)(24.49M)(23.77M)(42.44M)(45.65M)

Sagimet Biosciences Inc.

NASDAQ:SGMT

Intrinsic Alpha fair value

Locked

Current Price

$10.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.